Filter Results:
(554)
Show Results For
- All HBS Web
(554)
- People (1)
- News (214)
- Research (225)
- Events (1)
- Multimedia (11)
- Faculty Publications (139)
Show Results For
- All HBS Web
(554)
- People (1)
- News (214)
- Research (225)
- Events (1)
- Multimedia (11)
- Faculty Publications (139)
- December 2003
- Case
Manville Corporation Fiber Glass Group (C) (Abridged)
By: Lynn S. Paine
Manville Corp.'s senior managers are surprised when Japanese government officials advise them not to go forward with their plan to add a cancer warning label to diatomaceous earth (DE) products sold in Japan. The International Agency for Research on Cancer has ruled... View Details
Keywords: Risk and Uncertainty; Moral Sensibility; Safety; Government Administration; Cross-Cultural and Cross-Border Issues; Decision Choices and Conditions; Ethics; Announcements; Industrial Products Industry; Japan
Paine, Lynn S. "Manville Corporation Fiber Glass Group (C) (Abridged)." Harvard Business School Case 304-078, December 2003.
- November 2005 (Revised March 2006)
- Case
Genentech - Capacity Planning
By: Daniel C. Snow, Steven C. Wheelwright and Alison Berkley Wagonfeld
While facilitating a complex clinical approval process over the next two to three years for a family of new cancer drugs, Genentech must develop a long-term capacity plan for a major class of new cancer products. Adding to the complexity and uncertainty is the fact... View Details
Keywords: Factories, Labs, and Plants; Growth and Development Strategy; Management Style; Management Teams; Time Management; Product; Product Development; Business Processes; Performance Capacity; Planning; Risk and Uncertainty; Complexity; Pharmaceutical Industry
Snow, Daniel C., Steven C. Wheelwright, and Alison Berkley Wagonfeld. "Genentech - Capacity Planning." Harvard Business School Case 606-052, November 2005. (Revised March 2006.)
- 21 Oct 2015
- News
Mammogram Guidelines, Legal Caucus & A New Greater Bostonian
- 14 Apr 2011
- News
Clayton Christensen's Prescription For Health Care
- TeachingInterests
Health Systems
Instructor, Pasteur Institute CNAM School of Public Health (Paris, France), Mid-Career professionals from the National Institute of Cancer (INCA) View Details
- 17 Oct 2018
- Video
Unlocking the Potential of Precision Medicine
- 21 Feb 2013
- News
HBS Professor Frank Aguilar Dies at 80
- 13 Apr 2017
- News
What Precision Medicine Can Learn from the NFL
- February 2023
- Supplement
Dr. Andrea Pusic, Video Supplement
By: Robert S. Kaplan
Video supplement to aid in the teaching of "Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care," HBS case no. 122-010. View Details
Kaplan, Robert S. "Dr. Andrea Pusic, Video Supplement." Harvard Business School Multimedia/Video Supplement 123-709, February 2023.
- 04 Oct 2017
- News
Researchers Combat Gender and Racial Bias in Artificial Intelligence
- 23 Feb 2011
- News
Clayton Christensen: The Survivor
- 27 Feb 2009
- News
Switzerland has the medical bills covered
- 30 Aug 2016
- First Look
August 30, 2016
experiences instead of possessions. Similarly, people enjoy greater happiness from spending time on or with others and from acquiring experiences—both extraordinary and ordinary. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=51544 August 17, 2016... View Details
Keywords: Carmen Nobel
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details
Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- 01 May 2019
- News
Getting Personal With Precision Medicine
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- 21 Jun 2018
- Video
KPMA HBX Live: Cracking the Data Aggregation Problem - Paul Giusti
- 12 Jul 2012
- News